Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar GreatStocks3728 (< 20) Submitted: 1/23/2010 9:16:54 AM : Outperform Start Price: $28.25 ACOR Score: -40.04

Great earnings ahead.

Featured Broker Partners


Advertisement